On February 3, 2026, Sangamo Therapeutics announced positive results from its Phase 1/2 STAAR study evaluating isaralgagene civaparvovec for treating Fabry disease, reporting data on 33 patients as of April 10, 2025, highlighting a positive mean annualized eGFR slope of 1.965 mL/min/1.73m²/year. This filing supports a Biologics License Application (BLA) submission under the FDA’s Accelerated Approval Program.